Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
2期
提前终止
NCT05025423
| 适应症 | Mantle Cell Lymphoma |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 7 人 |
|---|
| 干预（药物） | Venetoclax Oral Tablet [Venclexta] |
|---|
| 开始日期 | 2022年6月21日 |
|---|
| 完成日期 | 2025年5月14日 |
|---|
| 结果公布日 | 2026年6月9日 |
|---|
摘要
The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the combination of venetoclax with rituximab in this patient population yields a clinically acceptable proportion of overall responses (ORR, assessed by PET/CT with Lugano criteria) without chemotherapy.
Overall Response Rate (ORR) After Four Cycles of Venetoclax and Rituximab.
120 days · Participants
| Venetoclax and Rituximab in Patients Over 60 Yrs Old With Previously Untreated Mantle Cell Lymphoma | 4 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。